Basit öğe kaydını göster

dc.contributor.authorSendur, M. A. N.
dc.contributor.authorAksoy, S.
dc.contributor.authorZengin, N.
dc.contributor.authorAltundag, K.
dc.date.accessioned2020-01-28T08:06:24Z
dc.date.available2020-01-28T08:06:24Z
dc.date.issued2012
dc.identifier.issn0007-0920
dc.identifier.urihttps://doi.org/10.1038/bjc.2012.473
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504952/
dc.identifier.urihttp://hdl.handle.net/11655/21892
dc.description.abstractBackground: Increased adiposity may trigger signalling pathways that induce aromatase expression. As aromatase inhibitors exert their effects by blocking the aromatase enzyme, higher body mass index (BMI) can reduce the effect of aromatase inhibitors. Thus, we aimed to investigate retrospectively the effect of BMI on the efficacy of aromatase inhibitors in hormone receptor-positive postmenopausal patients with breast cancer. Methods: Newly diagnosed hormone receptor-positive breast cancer patients who were postmenopausal and non-metastatic were enrolled to the study. Patients with BMI ranging between 18.5 and 24.9 kg m−2 were considered as normal weight patients (Arm A, n=102), and patients with a BMI ranging ⩾25 kg m−2 were grouped as overweight and obese patients (Arm B, n=399). Results: In both normal weight and overweight patients, the baseline clinico-pathologic properties and the treatment history with radiotherapy and chemotherapy were similar, and with no statistically significant difference. In normal weight patients disease-free survival (DFS) rate was 93.7% and 77.6%, whereas in overweight and obese patients DFS rate was 96.8% and 85.5% in the first and third years, respectively, (P=0.08). Three year survival rate in Arm A patients was 98.3%, whereas in Arm B was 98.0% (P=0.57). When anastrozole was compared with letrozole in the subgroup analysis no difference with regard to DFS and overall survival was detected. Conclusion: These results, contradictory to the prior results, show that BMI has no worse effect on outcomes of aromatase inhibitors in postmenopausal hormone receptor-positive breast cancer patients. In the subgroup analysis, letrozole and anastrozole had similar survival outcomes.tr_TR
dc.language.isoentr_TR
dc.publisherCancer Research UKtr_TR
dc.relation.isversionof10.1038/bjc.2012.473tr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectPostmenopausaltr_TR
dc.subjectBreast cancertr_TR
dc.subjectLetrozoletr_TR
dc.subjectAnastrozoletr_TR
dc.subject.lcshOnkolojitr_TR
dc.titleEfficacy of Adjuvant Aromatase Inhibitor In Hormone Receptor-Positive Postmenopausal Breast Cancer Patients According To The Body Mass Indextr_TR
dc.typeinfo:eu-repo/semantics/articletr_TR
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalBritish Journal of Cancertr_TR
dc.contributor.departmentTemel Onkolojitr_TR
dc.identifier.volume107tr_TR
dc.identifier.issue11tr_TR
dc.identifier.startpage1815tr_TR
dc.identifier.endpage1819tr_TR
dc.description.indexWoStr_TR
dc.description.indexPubMedtr_TR
dc.fundingYoktr_TR


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster